Gene Therapy for Blood Disorders Market Poised for Robust Growth With Major Biotech Investments and Breakthrough Clinical Pipelines

The newly published report titled "Global Gene Therapy for Blood Disorders Market- By Trends, Industry Competition Analysis, Pipeline Analysis/Clinical Trial, Revenue (US$ Billions) and Forecast Till 2034." features in-depth analysis and an extensive market study, exploring its significant upcoming years industry factors.

The Gene Therapy for Blood Disorders Market Size is estimated to grow at a 15.3% CAGR during the forecast period for 2025-2034.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1156

Gene therapy, which involves the alteration of human genes to treat various diseases, holds considerable potential, particularly in addressing rare hematologic disorders such as sickle cell disease and hemophilia. An increasing number of biopharmaceutical companies are integrating gene-editing technologies-most notably CRISPR-Cas9-into their development pipelines to create precise, targeted therapies for these conditions. For instance, CRISPR Therapeutics, in partnership with Vertex Pharmaceuticals, is currently advancing CTX001, a CRISPR/Cas9-based gene therapy, through Phase I/II clinical trials aimed at treating sickle cell disease.

The market is expected to experience strong growth, driven by the rising incidence of genetic and blood-related disorders, the growing demand for personalized medicine, increased healthcare expenditures, and an expanding focus on research and development of novel genetic treatments within the hematology field. According to a study published in PLOS Medicine, the global prevalence of sickle cell anemia is projected to increase by approximately 30% by 2050, highlighting the urgent need for effective therapeutic solutions and contributing to market expansion.

Despite these favorable trends, the widespread adoption of gene therapies may be constrained by their high cost and ongoing concerns related to safety and long-term efficacy, presenting challenges that could impact market growth during the forecast period.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

The prominent players in the gene therapy for blood disorders industry include:
BioMarin Pharmaceutical Inc. (U.S.), Medgenics (U.S.), Spark Therapeutics (U.S.), bluebird bio, Inc. (U.S.), Shire (U.S.), CRISPR Therapeutics (U.S.), Freeline Therapeutics (U.K.), OrphageniX (U.S.), Errant Gene Therapeutics (U.S.), Sangamo Therapeutics (U.S.), Sigilon Therapeutics, Inc. (U.S.), uniQure (Netherlands), Angiocrine Bioscience (U.S.), and Sanofi Genzyme (U.S.), and other prominent players.

Gene Therapy for Blood Disorders Market Regional Analysis:
North America is predicted to account for the largest share of the gene therapy for blood disorders market during the forecast years, followed by Europe, owing to the rising prevalence of various blood disorders, well-developed healthcare systems, and increasing R&D investments to develop effective gene therapies to treat rare diseases. According to the Hemophilia Federation of America, Hemophilia affects 1 in 5,000 male births, and around 400 babies are born with hemophilia in the U.S annually. Worldwide 400,000 individuals are living with hemophilia, and approximately 20,000 people are living with it in the United States alone.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1156

The Global Gene Therapy for Blood Disorders Market Segments
The Global Gene Therapy for Blood Disorders Market Estimates (Value US$ Million) & Forecasts and Trend Analyses, 2021 to 2030 based on Indication
• Sickle Cell Anemia
• β-thalassemia
• Hemophilia B
• Hemophilia A
• Other Indication
The Global Gene Therapy for Blood Disorders Market Estimates (Value US$ Million) & Forecasts and Trend Analyses, 2021 to 2030 based on Mechanism of Action
• Gene Therapy
• Gene Editing
The Global Gene Therapy for Blood Disorders Market Estimates (Value US$ Million) & Forecasts and Trend Analyses, 2021 to 2030 based on Region
• Europe
• North America
• Latin America
• Asia Pacific
• Middle East & Africa
North America Gene Therapy for Blood Disorders Market Estimates Revenue (US$ Million) by Country, 2021 to 2030
• U.S.
• Canada
Europe Gene Therapy for Blood Disorders Market Estimates Revenue (US$ Million) by Country, 2021 to 2030
• Germany
• Spain
• France
• Russia
• Italy
• Rest of Europe
Asia Pacific Gene Therapy for Blood Disorders Market Estimates Revenue (US$ Million) by Country, 2021 to 2030
• India
• Japan
• China
• Australia & New Zealand
• South Korea
Latin America Gene Therapy for Blood Disorders Market Estimates Revenue (US$ Million) by Country, 2021 to 2030
• Brazil
• Mexico
• Rest of Latin America
The Middle East & Africa Gene Therapy for Blood Disorders Market Estimates Revenue (US$ Million) by Country, 2021 to 2030
• South Africa
• GCC Countries
• Rest of the Middle East & Africa

Read Overview Report- https://www.insightaceanalytic.com/report/global-gene-therapy-for-blood-disorders-market/1156

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.